May 2, 2017

The European Medicines Agency (EMA) have classified LIfT's enhanced allogeneic granulocyte therapy as a somatic cell therapy MP, a type of Advanced Therapeutic Medicinal Product (ATMP).

LIfT BioSciences CEO, Alex Blyth, commented that "ATMP status (rather than being a m...

April 19, 2017

Scientists are searching for people with a rare genetic mutation that can supercharge immune systems

Read Article

Please note: there are inferences made in this article that are not the views expressed by LIfT BioSciences Ltd

March 23, 2017

LIfT BioSciences has been announced as one of the winners of Medcity’s Collaborate to Innovate Award and grant.

The focus for the project work with Professor Farzin Farzaneh, Professor of Molecular Medicine at King’s College London, is to develop in-vitro evidence that...

February 6, 2017

LIfT BioSciences has joined the UK's leading BioIncubator, Stevenage Bioscience Catalyst (SBC), for the UK's most promising SMEs in the healthcare space. The move will give LIfT Bio access to a spectrum of state-of-the-art translational research labs and development ca...

January 31, 2017

LIfT BioSciences has successfully secured initial funding into its potentially breakthrough Cell Therapy for Pancreatic Cancer. The funding has come from a Top 20 Major BioPharma Company, who for the time being wishes to remain anonymous.

The research aims to demonstrat...

December 9, 2016

LIfT BioSciences has entered into partnership with Kings College London's Cell Therapy Unit and Clinical Research Facility to research and develop its breakthrough LIfT Cell Therapy for Pancreatic Cancer.

The Cell Therapy Unit is the largest manufacturing facility...

October 31, 2016

Ali Stunt, founder & CEO of Pancreatic Cancer Action, Founding Board Member and Awareness Group Lead for Pancreatic Cancer Europe has joined LIfT BioSciences Advisory Board. 

Ali brings the patient perspective to our work, having been a patient herself who survived Panc...

Please reload


Note: This website contains certain statements that are not historical facts and may be forward-looking statements, please see our legal notice. Links provided from this website to other web pages over which the company has no control, are so provided for convenience only and as such, the company neither endorses nor makes any representations as to the accuracy or any other aspect of the information contained in such other web pages.

Follow Us
  • LinkedIn
  • Twitter Basic Square

Disclaimer: The information, documents and graphic depictions (the "Information") published on this Web site are the property of LIfT BioSciences Ltd. LIfT BioSciences assumes no responsibility for errors or omissions in the Information on this website. In no event shall LIfT BioSciences be liable for any special, direct, indirect, consequential, or incidental damages or any damages whatsoever, whether in an action of contract, negligence or other tort, arising out of or in connection with the use of this Web site or the Information. LIfT BioSciences reserves the right to make additions, deletions, or modification to the Information on the Web site at any time without prior notice.

  • CEO's Linked-in
  • CEO's Twitter
  • LIfTBio on Facebook

©2016 LIfT BioSciences Ltd